These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. An evaluation of amikacin nephrotoxicity in the hematology/oncology population. Kiel PJ, Lo M, Stockwell D, Patel GP. Am J Ther; 2008; 15(2):131-6. PubMed ID: 18356633 [Abstract] [Full Text] [Related]
7. An overview of the safety of isepamicin in adults. Blum D. J Chemother; 1995 Jun; 7 Suppl 2():87-93. PubMed ID: 8622116 [Abstract] [Full Text] [Related]
9. Prospective randomized study of once-daily versus twice-daily amikacin regimens in patients with systemic infections. Karachalios GN, Houpas P, Tziviskou E, Papalimneou V, Georgiou A, Karachaliou I, Halkiadaki D. Int J Clin Pharmacol Ther; 1998 Oct; 36(10):561-4. PubMed ID: 9799062 [Abstract] [Full Text] [Related]
16. The efficacy and safety of isepamicin and ceftazidime compared with amikacin and ceftazidime in acute lower respiratory tract infection. Colardyn F. J Chemother; 1995 Jun; 7 Suppl 2():129-35. PubMed ID: 8622101 [Abstract] [Full Text] [Related]
17. [Dosing aminoglycosides once a day]. Blaser J. Schweiz Med Wochenschr Suppl; 1996 Jun; 76():39S-48S. PubMed ID: 8677418 [Abstract] [Full Text] [Related]